(RS)-1-(4-fluoro-2-methylphenyl)ethanol | 700-34-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (RS)-1-(4-fluoro-2-methylphenyl)ethanol
• 英文别名: 1-(4-fluoro-2-methylphenyl)ethan-1-ol；1-(4-fluoro-2-methylphenyl)ethanol；1-(4-fluoro-2-methyl-phenyl)-ethanol；1-(4-Fluor-2-methyl-phenyl)-aethanol
• CAS: 700-34-5
• 化学式: C₉H₁₁FO
• 分子量: 154.184
• InChiKey: OOZVPOAUVOHRHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (RS)-1-(4-fluoro-2-methylphenyl)ethanol 在 pyridinium chlorochromate 、 copper(I) bromide 作用下， 以 二氯甲烷 、 氯仿 、 乙酸乙酯 为溶剂， 反应 11.0h， 生成 2-bromo-1-(4-fluoro-2-methylphenyl)ethan-1-one
  参考文献：
  名称：

  Optimization of Inhibitors of the Tyrosine Kinase EphB4. 2. Cellular Potency Improvement and Binding Mode Validation by X-ray Crystallography

  摘要：

  Inhibition of the tyrosine kinase erythropoietin-producing human hepatocellular carcinoma receptor B4 (EphB4) is an effective strategy for the treatment of solid tumors. We have previously reported a low nanomolar ATP-competitive inhibitor of EphB4 discovered in silico by fragment-based high-throughput docking combined with explicit solvent molecular dynamics simulations. Here we present a second generation of EphB4 inhibitors that show high inhibitory potency in both enzymatic and cell-based assays while preserving the appealing selectivity profile exhibited by the parent compound. In addition, respectable levels of antiproliferative activity for these compounds have been obtained. Finally, the binding mode predicted by docking and molecular dynamics simulations is validated by solving the crystal structures of three members of this chemical class in complex with the EphA3 tyrosine kinase whose ATP-binding site is essentially identical to that of EphB4.

  DOI：

  10.1021/jm301187e
• 作为产物：
  描述：

  4'-氟-2'-甲基苯乙酮 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 1.0h， 以95%的产率得到(RS)-1-(4-fluoro-2-methylphenyl)ethanol
  参考文献：
  名称：

  HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND

  摘要：

  公开号：

  EP2940013B1

文献信息

• [EN] COMPOUNDS, COMPOSITIONS, AND METHODS OF USE<br/>[FR] COMPOSÉS, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：SAGE THERAPEUTICS INC

  公开号：WO2020243027A1

  公开（公告）日：2020-12-03

  Described herein are compounds that act as CYP46A1 inhibitors, compositions comprising these compounds, and methods of their use into treating neurodegenerative diseases and the like, or a pharmaceutically active salt thereof. The present invention relates to compounds represented by the formula wherein each symbol is as defined in the specification, or a pharmaceutically active salt thereof.

  本发明涉及作为CYP46A1抑制剂的化合物，包括这些化合物的组合物，以及它们用于治疗神经退行性疾病等方法，或其药用活性盐。本发明的化合物由以下公式表示，其中每个符号如说明书中所定义，或其药用活性盐。
• Exploring Tandem Ruthenium-Catalyzed Hydrogen Transfer and S_NAr Chemistry
  作者：Kurt Polidano、Benjamin G. Reed-Berendt、Anaïs Basset、Andrew J. A. Watson、Jonathan M. J. Williams、Louis C. Morrill

  DOI：10.1021/acs.orglett.7b03441

  日期：2017.12.15

  A hydrogen-transfer strategy for the catalytic functionalization of benzylic alcohols via electronic arene activation, accessing a diverse range of bespoke diaryl ethers and aryl amines in excellent isolated yields (38 examples, 70% average yield), is reported. Taking advantage of the hydrogen-transfer approach, the oxidation level of the functionalized products can be selected by judicious choice

  报道了一种通过电子芳烃活化对苯甲醇进行催化官能化的氢转移策略，该方法以优异的分离产率获得了各种定制的二芳基醚和芳基胺（38例，平均产率为70％）。利用氢转移方法，可以通过明智地选择简单和廉价的添加剂来选择功能化产物的氧化水平。
• Halogen-substituted heterocyclic compound
  申请人：UBE INDUSTRIES, LTD.

  公开号：US10000463B2

  公开（公告）日：2018-06-19

  A novel α-halogen-substituted thiophene compound or a pharmacologically acceptable salt thereof, which has a potent LPA receptor-antagonist activity and is useful as a medicament is provided.

  本研究提供了一种新型α-卤代噻吩化合物或其药理学上可接受的盐，该化合物具有强效的 LPA 受体拮抗剂活性，可用作药物。
• HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND
  申请人：UBE INDUSTRIES, LTD.

  公开号：EP2940013B1

  公开（公告）日：2018-02-21
• BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE
  申请人：Merck Patent GmbH

  公开号：EP2802575B1

  公开（公告）日：2017-12-27